MedMira Awarded China Patent to Complete IP Triple Crown

    Rapid Flow-Through Technology Patents in Three Major Global Markets

    HALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today
that it received a Notice on Grant of Patent Right For Invention (equivalent
to the Notice of Allowance in the United States) from the State Intellectual
Property Office (SIPO) of the People's Republic of China for its rapid
diagnostic device and assay (Chinese Patent Application No. 02819646.5). The
novel invention is the rapid flow-through technology (RFT) platform, the core
product engine upon which the company has built its successful line of rapid
tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's
IP "triple crown" along with similar patents awarded in the United States
(Patent Application No. 10/163,675) and the European Union (European Patent
No. EP1417489).
    "Patents on our core technology in three major global markets are
fundamental components of our plan to grow our business through strategic
partnerships. While we continue to pursue patent protection for our
progressive IP estate in additional markets, we can now fully engage in
collaborative relationships to tap opportunities in three of the most
lucrative markets of the $40 billion global diagnostics market," said Hermes
Chan, President and CEO, MedMira Inc. "These partnerships, taking shape in
various forms including licensing, commercialization, and contract
manufacturing, will enable both new business and new innovation opportunities
for MedMira."
    Through straightforward and affordable licensing agreements MedMira
offers its patented technology platform to diagnostics developers seeking a
clear path to the global diagnostics market. While other technologies pose
potential roadblocks for developers, MedMira provides a comprehensive, proven
solution. The rapid flow-through technology is the core innovation behind
MedMira's fully commercialized line of rapid tests. The tests can be used to
diagnose one or multiple diseases using one test device and a single drop of
specimen. MedMira's rapid tests have performed exceptionally well in rigorous
clinical trials, earning "gold standard" regulatory approvals in major
international markets including the United States, Canada, China, India, and
the European Union.
    Chan continued, "MedMira's technology development team continues to
advance our RFT platform and recently filed a United States patent application
for the next generation two step RFT platform. With this next generation RFT
platform, we are positioning ourselves and our product portfolio for future
market growth in personalized healthcare, when over-the-counter (OTC) rapid
testing for infectious diseases and other chronic conditions will be widely
available."

    About MedMira

    MedMira is a leading developer, manufacturer, and marketer of advanced
rapid diagnostics. Built on the Company's patented rapid flow-through
technology platform, MedMira's single and multiple rapid tests provide
hospitals, labs, clinics and individuals around the world with reliable,
diagnosis for diseases such as HIV and hepatitis C in just three minutes. The
company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)
and Multiplo(TM) brands in global markets, have achieved regulatory approvals
in Canada, the United States, China, Russia, India, and the European Union.
MedMira is an approved supplier to US Agency for International Development
(USAID) and the Pan American Health Organization (PAHO).
    In 2006, MedMira launched the Maple Biosciences division to develop and
commercialize diagnostic instruments based on biosensor technology platforms.
The new diagnostic solutions will enable routine laboratory tests to be
performed in a matter of minutes, increasing automation, and streamlining the
diagnosis of multiple conditions and diseases. Together MedMira and Maple
Biosciences will be leading participants in the emerging fields of
personalized medicine and molecular diagnostics. For more information visit
www.maplebio.com.
    MedMira's corporate offices, R&D, and manufacturing facilities are
located in Halifax, Nova Scotia, Canada. For more information visit MedMira's
website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, [email protected]